Navigation Links
Forterus Inc. Announces Free Outpatient Treatment to Military Veterans Back from War Zones
Date:6/8/2009

HUNTINGTON BEACH, Calif., June 8 /PRNewswire-FirstCall/ -- Forterus Inc. (Pink Sheets: FTER), which, through its ABTTC Inc. division, provides drug and alcohol rehabilitation and a variety of other healthcare services, with the highest levels of accreditation, announced today that it is renewing an offer to provide free outpatient treatment to military veterans who have returned from active duty from the Iraq or Afghanistan war zones within the last five years.

"We realize there is a significant amount of Post-Traumatic Stress Disorder among our veterans, who are fighting for our freedom," said Paul Howarth, Forterus founder and CEO. "This is an anxiety disorder often caused by exposure to terrifying, violent events. There is effective treatment available."

Mr. Howarth said stress disorder can have a significant negative impact on work and relationships. Symptoms include flashbacks and nightmares, sleeping difficulties and anger. "We will provide free outpatient treatment for up to five veterans three days a week for a maximum of one month at our Better Tomorrow Treatment Center in Murrieta, Calif.," Forterus' CEO said. "Significant discounts are also available for veterans who need our 28-day residential treatment program."

For more information about Forterus, and the variety of healthcare services it provides, including behavioral, intervention services, drug and alcohol rehabilitation, pain management and physical therapy, visit www.forterushealthcare.com and www.abttc.com .

    CONTACT:

    Paul Howarth, CEO
    888/257-8345
    ir@forterushealthcare.com

    Paul Knopick
    E & E Communications
    949/707-5365
    pknopick@eandecommunications.com
'/>"/>
SOURCE  Forterus Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 

Related medicine news :

1. Forterus Inc. Inks Agreement to Provide National Sales and Marketing Support for a North Carolina-Based Addiction Treatment Center
2. Forterus Inc. Announces Stock Buyback
3. Forterus Healthcare to Acquire Solutions 4 Recovery
4. Forterus Healthcare Continues Its Southern California Expansion, Completing Its Second Acquisition in Six Months
5. A Better Tomorrow Treatment Center Inc., a Forterus Subsidiary, to Be Featured On A & E Television Networks Intervention Program
6. Forterus Treatment Center, A Better Tomorrow, Featured in Major Network Program
7. Advertisement for Forterus Treatment Center, A Better Tomorrow, Featured on A & E Network
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Steaz Launches Organic Zero Calorie Sparkling Line 59893 1Steaz Launches Organic Zero Calorie Sparkling Line 59893 2Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 1Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 2Bioidentical Hormones a True Prevention for Breast Cancer 59889 1Bioidentical Hormones a True Prevention for Breast Cancer 59889 2